Incyte | INCY - Fremdkapital

Aktienkurs
97.80
Täglich Wechseln
2.08 2.17%
Monatlich
8.27%
Jährlich
61.84%
Q2 Prognose
92.62




Fremdkapital Veränderung Datum
Acadia Pharmaceuticals USD 0 0 2025-03
Agenus USD 169.66M 146.06M 2025-12
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Gilead Sciences USD 22.13B 6M 2025-12
Incyte USD 29.41M 785K 2026-03
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
MacroGenics USD 70M 256K 2025-12
Merck USD 39.97B 6B 2025-09
Moderna USD 610M 584M 2025-12
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 29.59B 5.35B 2025-12
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03